Design of dendritic macromolecules containing folate or methotrexate residues.
about
Dendrimers bind antioxidant polyphenols and cisplatin drugBiogenic and synthetic polyamines bind cationic dendrimersSynthesis and preliminary evaluation in vitro of novel naproxen-dendritic peptide conjugates.Targeting the efficacy of a dendrimer-based nanotherapeutic in heterogeneous xenograft tumors in vivoPoly(amidoamine) dendrimer-methotrexate conjugates: the mechanism of interaction with folate binding protein.Effect of Mass Transport in the Synthesis of Partially Acetylated Dendrimer: Implications for Functional Ligand-Nanoparticle Distributions.Design, synthesis, and biological functionality of a dendrimer-based modular drug delivery platform.Biologically optimized nanosized molecules and particles: more than just size.Dendritic systems in drug delivery applications.The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters.Surface-engineered dendrimers: a solution for toxicity issues.Role of nanocarrier systems in cancer nanotherapy.Understanding specific and nonspecific toxicities: a requirement for the development of dendrimer-based pharmaceuticals.Drug delivery using multifunctional dendrimers and hyperbranched polymers.Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives.Prospects of nano-material in breast cancer management.Effect of methotrexate conjugated PAMAM dendrimers on the viability of MES-SA uterine cancer cells.Generation dependent safety and efficacy of folic acid conjugated dendrimer based anticancer drug formulations.Synthesis and characterization of G5 PAMAM dendrimer containing daunorubicin for targeting cancer cells.PEGylated PAMAM dendrimers as a potential drug delivery carrier: in vitro and in vivo comparative evaluation of covalently conjugated drug and noncovalent drug inclusion complex.Dynamics of cellular entry and drug delivery by dendritic polymers into human lung epithelial carcinoma cells.Dendrimeric systems and their applications in ocular drug delivery.Stimulation-Sensitive Drug Delivery SystemsRecent Progress on Nanostructures for Drug Delivery Applications
P2860
Q27307187-A9CD3AEA-2711-4769-A606-87887DF0254AQ28482718-440EFAD6-3B1E-4B34-A977-5A0B6A3DB74BQ33482970-397E3E05-FD70-47D7-8CD1-28592C01E3D6Q33640555-958848C9-63D9-410F-847D-C8546BAADD3EQ34473454-60DF23AF-604C-4D93-8D35-1C136CD7701AQ34666766-77435F9F-8818-47E4-8662-44E4DDE91102Q34952473-6D41DA26-FDA5-46C3-837B-DD4C8953D0C9Q35048175-B5745827-C05D-45DD-BF31-4AB46A540F99Q36945843-493FBC5F-0D05-45E1-8BC7-619BD23D5D20Q37278005-C83FA688-84A5-475C-A395-8BE7177CCAD6Q37372870-02E59804-5ACB-43D0-A9E1-3BA325140DD1Q37622867-1D7E50B6-C8C8-4D23-8644-4EFC04F7F5DDQ37694413-AC446845-E983-4949-B913-67AE1F3B8DBAQ37809880-176AC896-FF8C-4020-A36A-79E9098AF2DAQ37834336-2CDDFE5A-D79F-48D2-8A48-328FC7BED786Q38084156-5244A1D8-C7BA-4DA1-91DB-F8DC7DDC9DB5Q38940163-66B8BD68-F253-4279-9454-08D8446542A5Q38946521-82868A64-417C-42A2-9C30-BCB0044D3860Q39389155-FE99806C-3516-4365-8F96-A27A3752C888Q39754871-B1C6383C-F7C1-46A2-B5A8-FFC3DCE437FEQ44898669-56074715-18DF-44B9-A7D6-626EA6E0B3B6Q55563721-4A5CB606-CA9F-43AA-9CCA-E1773ADD2945Q57341240-0076C9B3-1AD9-4DE6-8C37-E8AAA9B5DD77Q59128282-F712A535-17DE-480E-AD83-28933E73E3DA
P2860
Design of dendritic macromolecules containing folate or methotrexate residues.
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Design of dendritic macromolecules containing folate or methotrexate residues.
@ast
Design of dendritic macromolecules containing folate or methotrexate residues.
@en
type
label
Design of dendritic macromolecules containing folate or methotrexate residues.
@ast
Design of dendritic macromolecules containing folate or methotrexate residues.
@en
prefLabel
Design of dendritic macromolecules containing folate or methotrexate residues.
@ast
Design of dendritic macromolecules containing folate or methotrexate residues.
@en
P356
P1476
Design of dendritic macromolecules containing folate or methotrexate residues.
@en
P304
P356
10.1021/BC990082K
P50
P577
1999-11-01T00:00:00Z